Lymphangioleiomyomatosis: Clinical features, management and basic mechanisms

Thorax

Volumn 54, Issue 3, 1999, Pages 254-264

  Johnson, Simon ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GROWTH FACTOR; PROGESTERONE; TRANSCRIPTION FACTOR;

ANGIOLIPOMA; ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEMOGRAPHY; DIET THERAPY; HORMONAL THERAPY; HUMAN; KIDNEY DISEASE; LUNG TRANSPLANTATION; LYMPHANGIOLEIOMYOMATOSIS; PATHOLOGY; PLEURA EFFUSION; PLEURODESIS; PNEUMOTHORAX; PREGNANCY; PRIORITY JOURNAL; RECURRENT DISEASE; SCREENING; SELF HELP; SOCIAL SUPPORT; THORACOCENTESIS; THORACOSCOPY; THORAX RADIOGRAPHY; TUBEROUS SCLEROSIS; LUNG TUMOR; RESEARCH; REVIEW;

HUMANS; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; RESEARCH;

EID: 0033088733     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.54.3.254     Document Type: Article

References (105)

1. Corrin B, Liebow AA, Friedman PJ. Pulmonary lymphangioleiomyomatosis. Am J Pathol 1975;79:348-82.
2. Taylor JR, Ryu J, Colby TV, et al. Lymphangioleiomyomatosis, clinical course in 32 patients. N Engl J Med 1990;323:1254-60.
3. Castro M, Shepherd CW, Gomez MR, et al. Pulmonary tuberous sclerosis. Chest 1995;107:189-95.
4. Johnson SR, Tattersfield AE. Rate of decline of lung function in patients with lymphangioleiomyomatosis: effect of menopause and progesterone treatment. Am J Respir Crit Care Med 1999 (submitted for publication).
5. Urban T, Lazor R, Lacronique M, et al. Pulmonary lymphangioleiomyomatosis in France: a retrospective study of 69 cases. Am J Respir Crit Care Med 1998;157:A806.
6. Kitaichi M, Nishimura K, Itoh H, et al. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med 1995;151:527-33.
7. Silverstein EF, Ellis K, Wolff M, et al. Pulmonary lymphangioleiomyomatosis. Am J Roentgenol 1974;120:832-50.
8. Wahedna I, Cooper S, Williams J, et al. Relation of pulmonary lymphangioleiomyomatosis to use of the oral contraceptive pill and fertility in the UK: a national case control study. Thorax 1994;49:910-4.
9. Shen A, Iseman, MD, Waldron JA, et al. Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous estrogens. Chest 1987;91:782-5.
10. Warren SE, Lee D, Martin V, et al. Pulmonary lymphangiomyomatosis causing bilateral pneumothorax during pregnancy. Ann Thorac Surg 1993;55:998-1000.
11. Brunelli A, Catalini G, Fianchini A. Pregnancy exacerbating unsuspected mediastinal lymphangioleiomyomatosis and chylothorax. Int J Gynecol Obstet 1996;52:289-290.
12. Hughes E, Hodder RV. Pulmonary lymphangiomyomatosis complicating pregnancy. A case report. J Reprod Med 1987;32:553-7.
13. Fukuda Y, Kawamoto M, Yamamoto A, et al. Role of elastic fibre degradation in emphysema-like lesions of pulmonary lymphangioleiomyomatosis. Hum Pathol 1990;21:1252-61.
14. Hayashi T, Flemming MV, Stetler-Stevenson WG, et al. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors in pulmonary lymphangioleiomyomatosis. Hum Pathol 1997;28:1071-8.
15. Peyrol S, Gindre D, Cordier JF, et al. Characterisation of the smooth muscle cell infiltrate and associated connective tissue matrix of lymphangioleiomyomatosis. Immunohistochemical and ultrastructural study of two cases. J Pathol 1992;168:387-95.
16. Popper HH, Gamperi R, Pongratz MG, et al. Chromosome typing in lymphangioleiomyomatosis of the lung with and without tuberous sclerosis. Eur Respir J 1993;6:753-9.
17. Yoshimatsu T, Tsuda T, Abe Y, et al. Immunohistochemical studies of pulmonary lymphangioleiomyomatosis and UIP. Am J Respir Crit Care Med 1996;153:A274.
18. Chan JKC, Tsang WYW, Pau MY, et al. Lymphangioleiomyomatosis and angiomyolipoma: closely related entities characterised by hamartomatous proliferation of HMB-45 positive smooth muscle. Histopathology 1993;22:445-55.
19. Tanaka H, Imada A, Morikawa T, et al. Diagnosis of pulmonary lymphangioleiomyomatosis by HMB 45 in surgically treated spontaneous pneumothorax. Eur Respir J 1995;8:1879-82.
20. Bonetti F, Chiodera P, Pea M, et al. Transbronchial biopsy in lymphangioleiomyomatosis of the lung: HMB 45 for diagnosis. Am J Surg Pathol 1993;17:1092-102.
21. Berger U, Khaghani A, Pomerance A, et al. Pulmonary lymphangioleiomyomatosis and steroid receptors: an immunocytochemical study. Am J Clin Pathol 1990;93:609-14.
22. Barberis M, Monti GP, Ziglio G, et al. Oestrogen and progesterone receptors, detection in pulmonary lymphangioleiomyomatosis. Am J Respir Crit Care Med 1996;153:A272.
23. Brock ET, Votto JJ. Lymphangioleiomyomatosis: treatment with hormonal manipulation. NY State J Med 1986;86:533-6.
24. Brentani MM, Carvalho CRR, Saldiva PH, et al. Steroid receptors in pulmonary lymphangioleiomyomatosis. Chest 1984;85:96-9.
25. Boelher A, Speich R, Russi EW, et al. Lung transplantation for lymphangioleiomyomatosis. N Engl J Med 1996;335:1275-80.
26. Ernst JC, Sohaey R, Cary JM. Pelvic lymphangioleiomyomatosis: atypical precursor to pulmonary disease. Chest 1994;106:1267-9.
27. Wolff M. Lymphangiomyoma: clinicopathologic study study and ultrastructural confirmation of its histiogenesis. Cancer 1973;31:988-1007.
28. Maziak DE, Kesten S, Rappaport DC, et al. Extrathoracic angiomyolipomas in lymphangioleiomyomatosis. Eur Respir J 1996;9:402-5.
29. Bernstein SM, Newell JD, Adamezyk D, et al. How common are renal angiomyolipomas in patients with lymphangioleiomyomatosis? Am J Respir Crit Care Med. 1995;152:2138-43.
30. Sawicka EH, Morris AJR. A report of two long surviving cases of pulmonary lymphangioleiomyomatosis and the response to progesterone therapy. Br J Dis Chest 1985;79:400-6.
31. Muller NL, Chiles C, Kullnig P. Pulmonary lymphangioleiomyomatosis: correlation of CT with radiographic and functional findings. Radiology 1990;175:335-9.
32. Burger CD, Hyatt RE, Staats BA. Pulmonary mechanics in lymphangioleiomyomatosis. Am Rev Respir Dis 1991;143:1030-3.
33. Itoh T, Mochizuki M, Kumazaki S, et al. Cystic pulmonary metastases of endometrial stromal sarcoma of the uterus mimicking pulmonary lymphangioleiomyomatosis: a case report with immunohistochemistry of HMB 45. Pathol Int 1997;47:725-9.
34. Sherrier RH, Chiles C, Roggli V. Pulmonary lymphangioleiomyomatosis CT findings. Am J Radiol 1989;153:937-40.
35. Brauner MW, Grenier P, Tijani K, et al. Pulmonary Langerhans cell histiocytosis: evolution of lesions on CT scans. Radiology 1997;204:497-502.
36. Johnson SR, Tattersfield AE. Treatment and outcome of lymphangioleiomyomatosis in the UK. Am J Respir Crit Care Med 1997;155:A327.
37. Calvo E, Amarillas L, Mateos MA, et al. Lymphangioleiomyomatosis chylous ascites and diet. Dig Dis Sci 1996;41:591-3.
38. Eliasson AH, Phillips YY, Tenholder MF. Treatment of lymphangioleiomyomatosis: a meta-analysis. Chest 1989;196:1352-5.
39. Cammaggi CM, Strocchi E, Giovannini M, et al. Medroxyprogesterone acetate plasma levels after multiple high dose administration in advanced cancer. Cancer Chemother Pharmacol 1983;11:19-22.
40. Hesselius I, Johansson EDB. Medroxyprogesterone acetate plasma levels after oral and intramuscular administration in a tong term study. Acta Obstet Gynecol Stand 1981;101s:65-70.
41. Viskum K. Pulmonary lymphangioleiomyomatosis. Monaldi Arch Chest Dis 1993;48:233-6.
42. van Milligen de Wit AW, Meilof-Planteydt MN. Successful treatment of pulmonary lymphangioleiomyomatosis with oophorectomy and medroxy-progesterone acetate: report of a case and brief review of the literature. Neth J Med 1990;36:246-51.
43. Adamson D, Heinrichs WL, Raybin DM, et al. Successful treatment of pulmonary lymphangiomyomatosis with oophorectomy and progesterone. Am Rev Respir Dis 1985;132:916-21.
44. Logan RF, Fawcett IW. Oophorectomy for pulmonary lymphangioleiomyomatosis: a case report. Br J Dis Chest 1985;79:98-100.
45. Cutler GB, Hoffman AR, Severdloff RS, et al. Therapeutic applications of LHRH and its analogues. Ann Intern Med 1985;102:643-57.
46. Rossi GA, Balbi B, Oddera S, et al. Response to treatment with an analogue of lutenising hormone releasing hormone in a patient with pulmonary lymphangioleiomyomatosis. Am Rev Respir Dis 1991;143:174-6.
47. Svendson TL, Viskum K, Hansborg N, et al. Pulmonary lymphangioleiomyomatosis: a case of progesterone receptor lymphangioleiomyomatosis treated with medroxyprogesterone, oophorectomy and tamoxifen. Br J Dis Chest 1984;78:267-71.
48. Klein M, Krieger O, Ruckser R, et al. Treatment of lymphangioleiomyomatosis by ovariectomy, interferon alpha 2b and tamoxifen: a case report. Arch Gynecol Obstet 1992;252:99-102.
49. De Bove P, Murris-Espin M, Buscail L, et al. Somatostatin receptors in pulmonary lymphangioleiomyomatosis: therapeutic relevance. Eur Respir J 1997;10(Suppl 25):2975.
50. O'Brien JD, Lium JH, Parosa JF, et al. Lymphangioleiomyomatosis: recurrence in the allograft after single lung transplantation. Am J Respir Crit Care Med 1995;151:2033-6.
51. Bittman I, Dose TB, Muller C, et al. Lymphangioleiomyomatosis: recurrence after single lung transplantation. Hum Pathol 1997;28:1420-3.
52. Nine JS, Yousem SA, Paradis IL, et al. Lymphangioleiomyomatosis: recurrence after lung transplantation. J Heart Lung Transplant 1994;13:714-9.
53. Johnson SR, Knox AJ, Tattersfield AE. Pregnancy in lymphangioleiomyomatosis. Thorax 1998;52(Suppl 6):A65.
54. Steiner MS, Goldman SM, Fishman EK, et al. The natural history of renal angiomyolipoma. J Urol 1993;150:1782-6.
55. Van Baal JG, Smits NJ, Keeman JN, et al. The evolution of renal angiomyolipomas in patients with tuberous sclerosis. J Urol 1994;152:35-8.
56. Kennelly MJ, Grossman HB, Cho KJ. Outcome and analysis of 42 cases of renal angiomyolipoma. J Urol 1994;152:1988-91.
57. Lemaitre L, Yann R, Dubrulle F, et al. Renal angiomyolipoma: growth followed up with CT and/or US. Radiology 1995;197:598-602.
58. Bosniak MA. Angiomyolipoma (hamartoma) of the kidney: a preoperative diagnosis is possible in virtually every case. Urol Radiol 1981;3:135-42.
59. Hammadeh MY, Thomas K, Philip T, et al. Renal cell carcinoma containing fat mimicking angiomyolipoma: demonstration with CT scan and histopathology. Eur Radiol 1998;8:228-9.
60. Conrad S, Wagner B, Hamper K, et al. Renal-cell carcinoma and angiomyolipoma with lymphangiomyomatosis. Urologe-Ausgabe 1994;33:76-9.
61. Peccatori I, Pitingolo F, Battini G, et al. Pulmonary lymphangioleiomyomatosis and renal papilliary cancer: incomplete expression of tuberous sclerosis? Nephrol Dialysis Transplant 1997;12:2740-3.
62. Han YM, Kim JK, Roh BS, et al. Renal angiomyolipoma: selective arterial embolization - effectiveness and changes in angiomyogenic components in long-term follow-up. Radiology 1997;204:65-70.
63. Valensi QJ. Pulmonary lymphangiomyoma, a probable forme fruste of tuberous sclerosis. Am Rev Respir Dis 1973;108:1411-5.
64. The TSCI Consortium. Identification of the TSCI gene on chromosome 9q34. Science 1997;277:805-8.
65. European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterisation of the tuberous sclerosis gene on chromosome 16. Cell 1993;75:1305-15.
66. Gomez MR. Phenotypes of the tuberous sclerosis complex with a revision of the diagnostic criteria. In: Johnson WG, Gomez MR, eds. Tuberous sclerosis and allied disorders. New York: The New York Academy of Sciences, 1991:1-7.
67. Roach ES, Smith M, Huttenlocher P, et al. Report of the diagnostic criteria committee of the National Tuberous Sclerosis Association. J Child Neurol 1992;7:221-4.
68. Johnson SR, Pitt A, Tattersfield AE, et al. The tuberous sclerosis 2 gene product tuberin is expressed in human airway smooth muscle and upregulated by airway smooth muscle mitogens. Am J Respir Crit Care Med 1997;4:A902.
69. Smolarek TA, Wessner LL, McCormack FX, et al. Evidence that lymphangioleiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 1998;62:810-5.
70. Vrtel R, Verhoef S, Bouman K, et al. Identification of a nonsense mutation at the 5′ end of the TSC2 gene in a family with a presumptive diagnosis of tuberous sclerosis complex. J Med Genet 1996;33:47-51.
71. Gilbert JR, Kumar A, Kandt RS, et al. Mutation analysis of the tuberous sclerosis-2 gene. Am J Hum Genet 1995;57:1228.
72. Wilson PJ, Ramesh V, Kristiansen A, et al. Novel mutations detected in the TSC2 gene from both sporadic and familial TSC2 patients. Hum Mol Genet 1996;5:249-56.
73. Green AJ, Smith M, Yates JRW. Loss of heterozygosity on chromosome 16p13.3 in hamartomas from tuberous sclerosis patients. Nature Genet 1994;6:193-6.
74. Green AJ, Johnson PH, Yates JRW. The tuberous sclerosis gene on chromosome 9q34 acts as a growth suppressor. Hum Mol Genet 1994;3:1833-4.
75. Henske EP, Neumann HPH, Scheitauer BW, et al. Loss of heterozygosity in the tuberous sclerosis (TSC-2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas. Genes Chromosomes Cancer 1995;13:295-98.
76. Wienecke R, Koenig A, DeClue JE. Identification of tuberin, the tuberous sclerosis-2 product posses specific rap 1 gap activity. J Biol Chem 1995;270:16409-14.
77. Xiao G, Shoarinejad F, Jin F, et al. The tuberous sclerosis 2 gene product tuberin functions as a rab5GTPase activating protein (GAP) in modulating endocytosis. J Biol Chem 1997;272:6097-100.
78. Vossler MR, Yao H, York RID, et al. cAMP activates MAP kinase and Elk-I through a B-Raf and Rap1-dependent pathway. Cell 1997;89:73-82.
79. Kitayama H, Sugimoto Y, Matsuzaki T, et al. A ras-related gene with transformation suppressor activity. Cell 1989;56:77-84.
80. Yoshida Y, Kawata M, Miura Y, et al. Microinjection of smg/rap1/Krev-1 p21 into Swiss 3T3 cells induces DNA synthesis and morphological changes. Mol Cell Biol 1992;12:3407-14.
81. Soucek T, Pusch O, Wienecke R, et al. Role of the tuberous sclerosis gene-2 product in cell cycle control. J Biol Chem 1997;272:29301-8.
82. Jin F, Wienecke R, Xiao GH, et al. Suppression of tumourigenicity by the wild type tuberous sclerosis 2. Proc Natl Acad Sci USA 1996;93:9154-9.
83. Basu TN, Gutmann DH, Fletcher JA, et al. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992;356:713-5.
84. Bucci C, Parton RG, Mather IH, et al. The small GTPase rab5 functions as a regulatory factor in the early endocytic pathway. Cell 1992;70:715-28.
85. Van Slegtenhorst M, Nellist M, Negelkerken B, et al. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hunt Mol Genet 1998;7:1053-7.
86. Stovin PGI, Lim LC, Flower CDR, et al. The lungs in lymphangioleiomyomatosis and in tuberous sclerosis. Thorax 1975;30:497.
87. Usuki J, Horiba K, Chu SC, et al. Immunohistochemical analysis of proteins of the BCL-2 family in pulmonary lymphangioleiomyomatosis. Arch Patrol Lab Med 1998;122:895-902.
88. Kalassian KG, Doyle R, Kao P, et al. Lymphangioleiomyomatosis: new insights. Am J Respir Crit Care Med 1997;155:1183-6.
89. Pea M, Bonetti F, Zamboni G, et al. Melanocyte marker HMB-45 is regularly expressed in angiomyolipoma of the kidney. Pathology 1991;23:185-8.
90. Hoon V, Thung SN, Kaneko M, et al. HMB 45 reactivity in in renal angiomyolipoma and lymphangioleiomyomatosis. Arch Pathol Lab Med 1994;118:732-4.
91. Flieder DB, Travis WD. Clear cell "sugar" tumour of the lung: association with lymphangioleiomyomatosis and multifocal micronodular pneumocyte hyperplasia in a 32 year old woman with tuberous sclerosis. Am J Surg Pathol 1997;21:1242-7.
92. Bonetti F, Pea M, Martignoni G, et al. Clear-cell (sugar) tumor of the lung is a lesion strictly related to angiomyolipoma: the concept of a family of lesions characterized by the presence of the perivascular epithelioid cells (PEC). Pathology 1995;26:230-6.
93. Kimura N, Watanabe M, Date F, et al. HMB-45 and tuberin in hamartomas associated with tuberous sclerosis. Mod Pathol 1997;10:952-9.
94. Adema GJ, de Boer AJ, Vogel AM, et al. Molecular characterisation of the melanocyte lineage specific antigen gp 100. J Biol Chem 1994;269:20126-33.
95. Usuki J, Horiba K, Matsumoto Y, et al. Inverse correlation between markers of cell proliferation and expression of melanosomal antigens in smooth muscle cells in lymphangioleiomyomatosis and in cultured melanoma cell lines. Am J Respir Crit Care Med 1998;157:A806.
96. Johnson SR, Knox AJ. Synthetic functions of airway smooth muscle in asthma. TIPS 1997;18:288-92.
97. Inoue Y, Barker EA, King Jr. TE, et al. Immunohistochemistry of basic fibroblast growth factor receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis. Am J Respir Crit Care Med 1998;157:A74.
98. Glassberg MK, Alexis J, Krieger BP, et al. Platelet derived growth factor β receptor and B chain are more abundant in LAM. Am J Respir Crit Care Med 1997;155:A327.
99. Yoshimatsu T, Abe Y, Tsuda T, et al. The tissue angiotensin system in pulmonary lymphangioleiomyomatosis and UIP. Am J Respir Crit Care Med 1997;155:A327.
100. 1. Am J Respir Cell Mol Biol 1998;18:823-33.
101. D'Armiento CT, Chen M, Selman A, et al. Specific expression of an embryonic transcription factor in the spindle cells of lymphangioleiomyomatosis. Am J Respir Crit Care Med 1998;157:A806.
102. Hess JL. Chromosomal translocations in benign tumors: the HMGI proteins. Am J Clin Pathol 1998;109:251-61.
103. Chiappetta G, Avantaggiato V, Visconti R, et al. A High-level expression of the HMGI-(y) gene during embryonic-development. Oncogene 1996;13:2439-46.
104. Williams AJ, Powell WL, Collins T, et al. HMGI(Y) expression in human uterine leiomyomata: involvement of another high-mobility group architectural factor in a benign neoplasm. Am J Pathol 1997;150:911-18.
105. Xiao S, Lux ML, Reeves R, et al. HMGI(Y) activation by chromosome 6p21 rearrangements in multilineage mesenchymal cells from pulmonary hamartoma. Am J Pathol 1997;150:901-10.